Clinical Trial Update: 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. [Phase 2]

View source ↗

Summary

Phase 2 first-line trial evaluating continuous-capecitabine with oxaliplatin and bevacizumab administered every two weeks in metastatic colorectal cancer; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Capecitabine (Xeloda) (Capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Unidad Integral de Investigación en Oncología S.L. | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED